Modeling Center of Excellence Practices to Improve the Care of Patients With Biomarker-Driven Thyroid Cancer or Non-Small-Cell Lung Cancer

April 2, 2024
Holy Name Medical Center
 
Targeted therapies are driving a rapidly evolving landscape in cancer care. Are your molecular testing procedures optimized to guide treatment for your patients diagnosed with NSCLC or thyroid cancer? Are you using the right tests at the right times for the right patients? Assess your current practices and procedures, and create a plan to optimize testing and treatment, through this innovative, customized, point-of-care learning program designed to help you enhance your processes and improve your ability to implement the most appropriate biomarkers and assays to inform treatment selection. Collaborate with expert faculty to develop strategies to overcome the barriers you face and better individualize therapy according to molecular testing results to improve outcomes for your patients with thyroid cancer or NSCLC. Join your colleagues in this new frontier of personalized medicine today!
 

Educational Partner: Academy for Continued Healthcare Learning (ACHL)

Commercial Support: Support for this activity has been provided through an educational grant from Lilly.

Target Audience

This activity is intended for oncologists, pathologists and the multidisciplinary team practicing in academic and community settings who treat patients with NSCLC or thyroid cancer.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Develop improved models for early and effective biomarker testing
  • Identify appropriate patients and optimize treatment for RET-targeted therapy
  • Develop strategies to mitigate challenges and barriers to optimizing RET testing for patients with NSCLC and thyroid cancer
Additional information
ACGME/ABMS Core Competencies: 
Patient Care and Procedural Skills
Medical Knowledge
Practice-based Learning and Improvement
Interpersonal and Communication Skills
For more information, please contact:
CME Coordinator Contact Name: 
ACHL
CME Coordinator Contact Phone: 
877-444-8435 ext 160
Summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Event starts: 
04/02/2024 - 8:00am
Event ends: 
04/02/2024 - 9:00am
Activity opens: 
04/02/2024
Activity expires: 
07/02/2024
Webinar
Teaneck, NJ
United States
WANT TO KNOW MORE?
Visit the Academy for Continued Healthcare Learning (ACHL) website!
 
Questions?
Contact ACHL via their website.
 
ACCESSIBILITY The University of Chicago is committed to providing equal access appropriate to need and circumstances and complies fully with legal requirements of the Americans with Disabilities Act. If you are in need of special accommodation, please contact our office at https://www.achlcme.org.

The University of Chicago reserves the right to cancel or postpone this conference due to unforeseen circumstances. In the unlikely event this activity must be cancelled or postponed, the registration fee will be refunded; however, The University of Chicago is not responsible for any related costs, charges, or expenses to participants, including fees assessed by airline/travel/lodging agencies.
FACULTY
  Maria Arcila, MD
  Attending Pathologist and Laboratory Director, Diagnostic Molecular Pathology
  Medical Director, Molecular Hematopathology
  Memorial Sloan Kettering Cancer Center
  New York, NY
 
  Marcia Brose, MD, PhD, FASCO
  Director, Cancer Services
  Vice Chair, Hematology and Medical Oncology
  Co-Director Community Based Clinical Trials
  Sidney Kimmel Cancer Center - Jefferson Health
  Philadelphia, PA
 
  Lori Wirth, MD
  Associate Professor
  Harvard Medical School
  Medical Director
  Massachusetts General Hospital’s Center for Head and Neck Cancers
  Boston, MA
 

  Christine Bestvina, MD (Content Reviewer)
  Associate Professor
  Department of Medicine, Section of Hematology/Oncology
  University of Chicago Medicine
  Chicago, IL
 
 
Disclosure Declarations
As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks everyone in a position to control the content of an education activity to disclose all financial relationships with any ineligible companies. This includes any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if a financial relationship, in any amount, exists between the person in control of content and an ineligible company during the past 24 months, and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. Mechanisms are in place to identify and mitigate any relevant financial relationships prior to the start of the activity.

Additionally, The University of Chicago Pritzker School of Medicine requires Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration at first mention and where appropriate in the content.
Physician Credit
The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Chicago Pritzker School Of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
Physician assistants, nurse practitioners, and nurses may participate in this educational activity and earn a certificate of completion as AAPA, AANP, and ANCC accept AMA PRA Category 1 Credits™ through their reciprocity agreements.
 
Please Note: The credit claiming process will close three months after the conference end date. Requests to claim credit after three months will be subject to additional fees.
REGISTRATION: Registration is not open to the public.
For questions or more information, visit the ACHL website or click the button below!
 
 
Please login or create an account to proceed.